Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275036 | 0.90 | L3MBTL1 (0.64) | NPC1L3MBTL1TDP1LMNANPSR1 | |
| SCHEMBL2273634 | 0.86 | SERPINE1 (0.60) | L3MBTL1TDP1LMNANPSR1PYGL | |
| SCHEMBL2274811 | 0.85 | PYGM (0.57) | L3MBTL1TDP1LMNAPYGLSERPINE1 | |
| SCHEMBL2292513 | 0.85 | SERPINE1 (0.62) | L3MBTL1TDP1LMNANPSR1SERPINE1 | |
| SCHEMBL2274830 | 0.84 | MEN1 (0.54) | NPC1PYGLSERPINE1MAPT | |
| SCHEMBL4210617 | 0.84 | AKR1C3 (0.51) | NPC1DHODHCYP2C9CYP2C19MAPT | |
| SCHEMBL2274965 | 0.84 | L3MBTL1 (0.49) | L3MBTL1TDP1LMNANPSR1CYP2C9 | |
| SCHEMBL2276447 | 0.84 | SERPINE1 (0.54) | TDP1PYGLCYP2C9CYP2C19SERPINE1 | |
| SCHEMBL6432759 | 0.83 | PYGL (0.69) | L3MBTL1TDP1LMNAPYGL | |
| SCHEMBL2269555 | 0.82 | HPSE (0.55) | NPC1TDP1PYGLSERPINE1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | NPC1 4836/4885L3MBTL1 3822/4885TDP1 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.